0
0
January 25, 2024 — Swedish neuroscientists have unveiled a groundbreaking blood test that can identify the risk of Alzheimer’s disease a remarkable 15 years before the onset of symptoms in individuals over the age of 50. This novel test measures levels of a specific blood biomarker, phosphorylated tau (p-tau), providing a non-invasive and cost-effective alternative to current methods that require scans or spinal taps.
Alzheimer’s disease, the most common type of dementia impacting memory and cognitive functions, poses a significant health challenge globally. Current methods to detect beta amyloid and tau buildup in the brain, indicative of Alzheimer’s pathology, involve inaccessible and expensive procedures like brain scans or spinal taps.
The study, published in the journal JAMA Neurology, revealed that the newly developed blood test achieved an impressive accuracy rate. It demonstrated a 96 percent accuracy in identifying elevated levels of beta amyloid and up to 97 percent accuracy in identifying tau, crucial indicators of Alzheimer’s disease.
The research, led by Nicholas J. Ashton from the Department of Psychiatry and Neurochemistry at the University of Gothenburg, Sweden, showcased the effectiveness of the plasma p-tau217 assay as an initial screening tool in managing cognitive impairment. The blood test proved to be just as accurate as advanced methods, such as cerebrospinal fluid tests and brain scans, in revealing Alzheimer’s pathology in the brain.
“What was impressive with these results is that the blood test was just as accurate as advanced testing like cerebrospinal fluid tests and brain scans at showing Alzheimer’s disease pathology in the brain,” Ashton stated, as reported by CNN.
The ALZpath pTau217 assay, utilized in this study, is a commercially available tool developed by the company ALZpath. It is estimated that the test’s cost could range between $200 and $500, making it a more accessible option for widespread use.
The potential implications of this blood test are immense. It offers a robust and accurate blood-based biomarker for a more comprehensive assessment of cognitive impairment, especially in settings where advanced testing may be limited. The researchers emphasize that the use of a blood biomarker intends to enhance early and precise Alzheimer’s disease diagnosis, leading to improved patient management and timely access to disease-modifying therapies.
As the scientific community continues to explore innovative solutions for Alzheimer’s detection and intervention, this blood test stands as a promising development in the quest to revolutionize Alzheimer’s diagnostics and improve patient outcomes.
